Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects

M D Gow, C B Seymour, R J Mairs, Marie Boyd, W V Prestiwch, C E Mothersill

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Targeted radiotherapy is a potentially useful treatment for some cancers and may be potentiated by bystander effects. However, without estimation of absorbed dose, it is difficult to compare the effects with conventional external radiation treatment.  Using the Vynckier - Wambersie dose point kernel, a model for dose rate evaluation was created allowing for calculation of absorbed dose values to two cell lines transfected with the noradrenaline transporter (NAT) gene and treated with [(131)I]MIBG.  The mean doses required to decrease surviving fractions of UVW/NAT and EJ138/NAT cells, which received medium from [(131)I]MIBG-treated cells, to 25 - 30% were 1.6 and 1.7 Gy respectively. The maximum mean dose rates achieved during [(131)I]MIBG treatment were 0.09 - 0.75 Gy/h for UVW/NAT and 0.07 - 0.78 Gy/h for EJ138/NAT. These were significantly lower than the external beam gamma radiation dose rate of 15 Gy/h. In the case of control lines which were incapable of [(131)I]MIBG uptake the mean absorbed doses following radiopharmaceutical were 0.03 - 0.23 Gy for UVW and 0.03 - 0.32 Gy for EJ138.  [(131)I]MIBG treatment for ICCM production elicited a bystander dose-response profile similar to that generated by external beam gamma irradiation but with significantly greater cell death.

LanguageEnglish
Pages1-23
Number of pages23
JournalDose-response : a publication of International Hormesis Society
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Bystander Effect
3-Iodobenzylguanidine
Dosimetry
Cells
Radiotherapy
Cell death
Gamma rays
Genes
Irradiation
Radiation
Radiopharmaceuticals
Gamma Rays
Therapeutics
Cell Death
Cell Line
Neoplasms

Keywords

  • mathematical modelling
  • bystander efects
  • radiopharmaceuticals

Cite this

Gow, M D ; Seymour, C B ; Mairs, R J ; Boyd, Marie ; Prestiwch, W V ; Mothersill, C E. / Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects. In: Dose-response : a publication of International Hormesis Society. 2014 ; Vol. 12, No. 1. pp. 1-23.
@article{64e3a67f81684b0f999e791daa3a4e6b,
title = "Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects",
abstract = "Targeted radiotherapy is a potentially useful treatment for some cancers and may be potentiated by bystander effects. However, without estimation of absorbed dose, it is difficult to compare the effects with conventional external radiation treatment.  Using the Vynckier - Wambersie dose point kernel, a model for dose rate evaluation was created allowing for calculation of absorbed dose values to two cell lines transfected with the noradrenaline transporter (NAT) gene and treated with [(131)I]MIBG.  The mean doses required to decrease surviving fractions of UVW/NAT and EJ138/NAT cells, which received medium from [(131)I]MIBG-treated cells, to 25 - 30{\%} were 1.6 and 1.7 Gy respectively. The maximum mean dose rates achieved during [(131)I]MIBG treatment were 0.09 - 0.75 Gy/h for UVW/NAT and 0.07 - 0.78 Gy/h for EJ138/NAT. These were significantly lower than the external beam gamma radiation dose rate of 15 Gy/h. In the case of control lines which were incapable of [(131)I]MIBG uptake the mean absorbed doses following radiopharmaceutical were 0.03 - 0.23 Gy for UVW and 0.03 - 0.32 Gy for EJ138.  [(131)I]MIBG treatment for ICCM production elicited a bystander dose-response profile similar to that generated by external beam gamma irradiation but with significantly greater cell death.",
keywords = "mathematical modelling, bystander efects, radiopharmaceuticals",
author = "Gow, {M D} and Seymour, {C B} and Mairs, {R J} and Marie Boyd and Prestiwch, {W V} and Mothersill, {C E}",
year = "2014",
month = "1",
doi = "10.2203/dose-response.13-001.Mothersill",
language = "English",
volume = "12",
pages = "1--23",
journal = "Dose-response : a publication of International Hormesis Society",
issn = "1559-3258",
publisher = "International Dose-Response Society",
number = "1",

}

Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects. / Gow, M D; Seymour, C B; Mairs, R J; Boyd, Marie; Prestiwch, W V; Mothersill, C E.

In: Dose-response : a publication of International Hormesis Society, Vol. 12, No. 1, 01.2014, p. 1-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects

AU - Gow, M D

AU - Seymour, C B

AU - Mairs, R J

AU - Boyd, Marie

AU - Prestiwch, W V

AU - Mothersill, C E

PY - 2014/1

Y1 - 2014/1

N2 - Targeted radiotherapy is a potentially useful treatment for some cancers and may be potentiated by bystander effects. However, without estimation of absorbed dose, it is difficult to compare the effects with conventional external radiation treatment.  Using the Vynckier - Wambersie dose point kernel, a model for dose rate evaluation was created allowing for calculation of absorbed dose values to two cell lines transfected with the noradrenaline transporter (NAT) gene and treated with [(131)I]MIBG.  The mean doses required to decrease surviving fractions of UVW/NAT and EJ138/NAT cells, which received medium from [(131)I]MIBG-treated cells, to 25 - 30% were 1.6 and 1.7 Gy respectively. The maximum mean dose rates achieved during [(131)I]MIBG treatment were 0.09 - 0.75 Gy/h for UVW/NAT and 0.07 - 0.78 Gy/h for EJ138/NAT. These were significantly lower than the external beam gamma radiation dose rate of 15 Gy/h. In the case of control lines which were incapable of [(131)I]MIBG uptake the mean absorbed doses following radiopharmaceutical were 0.03 - 0.23 Gy for UVW and 0.03 - 0.32 Gy for EJ138.  [(131)I]MIBG treatment for ICCM production elicited a bystander dose-response profile similar to that generated by external beam gamma irradiation but with significantly greater cell death.

AB - Targeted radiotherapy is a potentially useful treatment for some cancers and may be potentiated by bystander effects. However, without estimation of absorbed dose, it is difficult to compare the effects with conventional external radiation treatment.  Using the Vynckier - Wambersie dose point kernel, a model for dose rate evaluation was created allowing for calculation of absorbed dose values to two cell lines transfected with the noradrenaline transporter (NAT) gene and treated with [(131)I]MIBG.  The mean doses required to decrease surviving fractions of UVW/NAT and EJ138/NAT cells, which received medium from [(131)I]MIBG-treated cells, to 25 - 30% were 1.6 and 1.7 Gy respectively. The maximum mean dose rates achieved during [(131)I]MIBG treatment were 0.09 - 0.75 Gy/h for UVW/NAT and 0.07 - 0.78 Gy/h for EJ138/NAT. These were significantly lower than the external beam gamma radiation dose rate of 15 Gy/h. In the case of control lines which were incapable of [(131)I]MIBG uptake the mean absorbed doses following radiopharmaceutical were 0.03 - 0.23 Gy for UVW and 0.03 - 0.32 Gy for EJ138.  [(131)I]MIBG treatment for ICCM production elicited a bystander dose-response profile similar to that generated by external beam gamma irradiation but with significantly greater cell death.

KW - mathematical modelling

KW - bystander efects

KW - radiopharmaceuticals

U2 - 10.2203/dose-response.13-001.Mothersill

DO - 10.2203/dose-response.13-001.Mothersill

M3 - Article

VL - 12

SP - 1

EP - 23

JO - Dose-response : a publication of International Hormesis Society

T2 - Dose-response : a publication of International Hormesis Society

JF - Dose-response : a publication of International Hormesis Society

SN - 1559-3258

IS - 1

ER -